 |
1 Product |  |
0 Diseases | | 1 Product |
|
1 Trial |  |
11 News |  |
- | ES2B-C001 / ExpreS2ion
Enrollment open: A First-in-human, Clinical Trial Assessing the Safety of ES2B-C001-S01 With or Without [Adjuvant] in Patients With HER2 Expressing Metastatic Breast Cancer. (clinicaltrials.gov) - Jan 9, 2025
P1, N=27, Recruiting, Sponsor: ExpreS2ion Biotechnologies
Not yet recruiting --> Recruiting
- | ES2B-C001 / ExpreS2ion
New P1 trial: A First-in-human, Clinical Trial Assessing the Safety of ES2B-C001-S01 With or Without [Adjuvant] in Patients With HER2 Expressing Metastatic Breast Cancer. (clinicaltrials.gov) - Dec 26, 2024
P1, N=27, Not yet recruiting, Sponsor: ExpreS2ion Biotechnologies
- ||| ABNCoV2 / Bavarian Nordic
Trial completion, Trial completion date: ABNCoV2 Vaccine in SARS-CoV-2 (COVID-19) Seronegative and Seropositive Adult Subjects (clinicaltrials.gov) - Sep 26, 2024
P2, N=197, Completed, Sponsor: Bavarian Nordic
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial completion date: Feb 2024 --> Oct 2023
- ||||||| ABNCoV2 / Bavarian Nordic
Trial completion: ABNCoV2-03: ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 (clinicaltrials.gov) - Oct 27, 2023
P3, N=4223, Completed, Sponsor: Bavarian Nordic
Active, not recruiting --> Completed | Trial completion date: Feb 2024 --> Oct 2023 Active, not recruiting --> Completed
- ES2B-C001 / ExpreS2ion
Preclinical activity of ES2B-C001, a human candidate HER-2 virus-like particle (VLP) vaccine, against mammary carcinoma onset and metastasis (Section 24; Poster Board #7) - Mar 14, 2023 - Abstract #AACR2023AACR_2594;
Antibodies inhibited the 3D growth of human HER-2+++ and HER-2++ breast cancer cells, of trastuzumab resistant cells and of gastric carcinoma cells. Vaccination increased interferon-gamma secreting cells in the spleen, as evaluated by ELISPot (21
- || ABNCoV2 / University of Copenhagen, Leiden University Medical Center, Bavarian Nordic, AdaptVac, ExpreS2ion, University of Tuebingen
P1 data, Journal: First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2. (Pubmed Central) - Mar 7, 2023
P1
The data support the need for additional clinical development of ABNCoV2 as a second-generation SARS-CoV-2 vaccine. The modular cVLP platform will accelerate vaccine development, beyond SARS-CoV-2.
- ||||| ABNCoV2 / Bavarian Nordic
Enrollment closed, Trial completion date, Trial primary completion date: ABNCoV2-03: ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 (clinicaltrials.gov) - Mar 7, 2023
P3, N=4000, Active, not recruiting, Sponsor: Bavarian Nordic
The modular cVLP platform will accelerate vaccine development, beyond SARS-CoV-2. Recruiting --> Active, not recruiting | Trial completion date: May 2023 --> Sep 2023 | Trial primary completion date: Dec 2022 --> Apr 2023
- Long-term immune response after boost dose of novel capsid virus-like particle (cVLP) vaccine against SARS-CoV-2 (B / 16) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_4865;
- | ES2B-C001 / ExpreS2ion, Herceptin (trastuzumab) / Roche
Journal: Prevention and Therapy of Metastatic HER-2 Mammary Carcinoma with a Human Candidate HER-2 Virus-like Particle Vaccine. (Pubmed Central) - Oct 29, 2022
ES2B-C001 is a promising candidate vaccine for the therapy of tumors expressing HER-2. Preclinical results warrant further development towards human clinical studies.
- ABNCoV2 / University of Copenhagen, Leiden University Medical Center, Bavarian Nordic, AdaptVac, ExpreS2ion, University of Tuebingen
Safety and immunogenicity of ABNCoV2, a virus-like particle based vaccine against COVID-19 in a phase 2 trial in healthy adults (Palavela) - Sep 24, 2022 - Abstract #VCongress2022V_Congress_73;
- |||||| ABNCoV2 / Bavarian Nordic
Enrollment open: ABNCoV2-03: ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 (clinicaltrials.gov) - Sep 21, 2022
P3, N=4000, Recruiting, Sponsor: Bavarian Nordic
Preclinical results warrant further development towards human clinical studies. Not yet recruiting --> Recruiting
- | ABNCoV2 / University of Copenhagen, Leiden University Medical Center, Bavarian Nordic, AdaptVac, ExpreS2ion, University of Tuebingen
Journal: A Capsid Virus-Like Particle-Based SARS-CoV-2 Vaccine Induces High Levels of Antibodies and Protects Rhesus Macaques. (Pubmed Central) - May 5, 2022
Upon SARS-CoV-2 challenge, a significant reduction in viral load was observed for both vaccine groups relative to the challenge control group, with no evidence of enhanced disease. Remarkably, neutralizing antibody titers against an original SARS-CoV-2 isolate and against variants of concern were comparable, indicating a potential for broad protection afforded by ABNCoV2, which is currently in clinical testing.
- || ABNCoV2 / University of Copenhagen, Leiden University Medical Center, Bavarian Nordic, AdaptVac, ExpreS2ion, University of Tuebingen
Frontiers in Immunology publishes article about ABNCoV2 https://t.co/HCx0Aug35d (Twitter) - Apr 19, 2022
- |||||||||| ABNCoV2 / Bavarian Nordic
New P3 trial: ABNCoV2-03: ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 (clinicaltrials.gov) - Apr 13, 2022
P3, N=4000, Not yet recruiting, Sponsor: Bavarian Nordic
- | ABNCoV2 / Bavarian Nordic
Trial completion: COUGH-1: Safety and Tolerability of COVID-19 Vaccine (ABNCoV2) (clinicaltrials.gov) - Mar 16, 2022
P1, N=45, Completed, Sponsor: Radboud University Medical Center
Remarkably, neutralizing antibody titers against an original SARS-CoV-2 isolate and against variants of concern were comparable, indicating a potential for broad protection afforded by ABNCoV2, which is currently in clinical testing. Active, not recruiting --> Completed
- || ABNCoV2 / Bavarian Nordic
Enrollment closed: ABNCoV2 Vaccine in SARS-CoV-2 (COVID-19) Seronegative and Seropositive Adult Subjects (clinicaltrials.gov) - Mar 4, 2022
P2, N=197, Active, not recruiting, Sponsor: Bavarian Nordic
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||| ES2B-C001 / ExpreS2ion
Clinical: ExpreS2ion provides an update on its novel breast cancer vaccine candidate ES2B-C001 https://t.co/YrwCDIo5bs (Twitter) - Feb 8, 2022
- || ABNCoV2 / University of Copenhagen, Leiden University Medical Center, Bavarian Nordic, AdaptVac, ExpreS2ion, University of Tuebingen, obecabtagene autoleucel (AUTO1) / Autolus
The week ahead Events #GI22: abstracts release - 18 Jan at 11pm CET / 5pm ET $ASND: TransCon PTH Ph3 data in hypoparathyroidism - Q1'22 $AUTL: Obe-cel Ph1 data in peripheral CNS lymphoma - Q1'22 $BAVA: ABNCoV2 additional Ph2 data booster study - Q1'22 1/2 (Twitter) - Jan 17, 2022
- | ABNCoV2 / Bavarian Nordic
Enrollment closed: COUGH-1: Safety and Tolerability of COVID-19 Vaccine (ABNCoV2) (clinicaltrials.gov) - Nov 22, 2021
P1, N=45, Active, not recruiting, Sponsor: Radboud University
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| ABNCoV2 / Bavarian Nordic
New P2 trial: ABNCoV2 Vaccine in SARS-CoV-2 (COVID-19) Seronegative and Seropositive Adult Subjects (clinicaltrials.gov) - Oct 14, 2021
P2, N=210, Recruiting, Sponsor: Bavarian Nordic
- | ABNCoV2 / Bavarian Nordic
New P1 trial: COUGH-1: Safety and Tolerability of COVID-19 Vaccine (ABNCoV2) (clinicaltrials.gov) - Apr 9, 2021
P1, N=42, Recruiting, Sponsor: Radboud University